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Introduction
Cancer is a disease characterized by genetic instability.
Although identification of novel therapeutic agents via molecu-
lar targeting offers the promise of great specificity coupled with
reduced systemic toxicity, specific inhibition of individual pro-
teins or signaling pathways faces the potential peril of being
subverted by the inherent genetic plasticity of cancer cells.
Cancer cells are very adept at adapting to noxious environ-
ments. Thus, hormone-dependent tumors eventually become
hormone-independent, either by receptor mutation or via activa-
tion of alternative pathways leading to receptor stimulation.
Similarly, cancer cells exposed to initially fatal levels of
chemotherapy eventually activate multiple and overlapping sig-
naling pathways to protect themselves from further harm, while
tumors deprived of oxygen upregulate a multifaceted transcrip-
tional response that allows them to cope successfully with the
hypoxic state.
If one assumes that cancer cells are always under moder-
ate to severe stress of one type or another, an approach to this
apparent dilemma might be to target the basic machinery that
allows cancer cells to adapt so successfully to stress. Cells
respond to stress by increasing synthesis of a number of molec-
ular chaperones (also known as heat shock proteins, or Hsps,
because they were first observed in cells exposed to elevated
temperature). These housekeeping proteins, as their name
implies, assist general protein folding and prevent nonfunctional
side reactions such as the nonspecific aggregation of misfolded
or unfolded proteins. However, within the last decade, one chap-
erone in particular, heat shock protein 90 (Hsp90), has
emerged as being of prime importance to the survival of cancer
cells. Hsp90 is constitutively expressed at 2- to 10-fold higher
levels in tumor cells compared to their normal counterparts,
suggesting that it may be critically important for tumor cell
growth and/or survival. A small molecule inhibitor of Hsp90, the
benzoquinone ansamycin 17-allylamino-17-desmethoxygel-
danamycin (17-AAG), has shown antitumor activity in several
human xenograft models, including colon, breast, and prostate
cancer (Basso et al., 2002; Kelland et al., 1999; Solit et al.,
2002). The drug is currently completing multi-institution phase I
clinical trials, and phase II trials are being planned. Other Hsp90
inhibitors are also at various stages of development. For a
detailed review of Hsp90 inhibitor drug development, including
a discussion of pharmacodynamic endpoints, see the recent
review by Maloney and Workman (2002). Why has this molecu-
lar target garnered so much recent interest?
What happens upon Hsp90 inhibition?
Discussion of Hsp90 function cannot be separated from a dis-
cussion of its small molecule inhibitors, particularly the benzo-
quinone ansamycin geldanamycin (GA), the first inhibitor of
Hsp90 to be identified. When Whitesell et al. first identified
Hsp90 as the intracellular protein to which GA binds, it was
unclear what effect drug binding had on chaperone activity
(indeed, the full extent of Hsp90 function was not appreciated)
(Whitesell et al., 1994). For several years prior, GA and related
benzoquinone ansamycins such as herbimycin A had been
used as tyrosine kinase inhibitors. In the initial report of GA
binding to Hsp90, we made the observation that, while GA did
not directly affect the kinase activity of p60v-src, drug addition to
v-src-transformed 3T3 cells dramatically shortened the half-life
of the protein without affecting its mRNA level or translation
rate, thus effectively reducing kinase activity by reducing the
intracellular content of kinase protein. An association of p60v-src
with Hsp90 had been described in the early 1980s, although the
reason for this association was not known (Oppermann et al.,
1981). In our report describing GA binding to Hsp90 and the
concomitant destabilization of v-src protein, we also observed a
rapid, apparent dissociation of p60v-src from Hsp90 in drug-treat-
ed cells, and we reasoned that this led to p60v-src instability
(Whitesell et al., 1994). Later studies revealed that the associa-
tion of client proteins, such as p60v-src, with Hsp90 was in fact
not fully lost in the presence of GA, but altered to become more
sensitive to detergent, and that GA-induced protein destabiliza-
tion was due to ubiquitination-dependent, proteasome-mediat-
ed protein degradation (Schneider et al., 1996). Thus, the
paradigm of the effects of Hsp90 inhibition on its client proteins
(e.g., p60v-src)—drug-induced alteration in Hsp90 association
followed rapidly by polyubiquitination and proteasome-mediat-
ed degradation—was already apparent in these initial studies.
The list of Hsp90 client proteins has grown strikingly over the
last several years, and it includes key components of multiple
signaling pathways utilized by cancer cells for growth and/or sur-
vival (for a review, see Neckers, 2002). Hsp90 clients are not lim-
ited to kinases, although a large number of kinases (e.g., HER2,
AKT, c-RAF-1) are clients. Ligand-dependent transcription fac-
tors (e.g., steroid receptors), transcription factors (e.g., HIF-1α)
containing PAS domains (“PAS” delineates a common motif
shared by the transcription factors PER, ARNT, and SIM), and,
importantly, mutated or chimeric signaling proteins (mutated
p53, NPM-ALK kinase, p210Bcr-Abl) are also Hsp90 clients. While
certain motifs to which Hsp90 binds (e.g., PAS domains) have
been described, there is no single Hsp90 binding motif, and the
rules that determine a requirement for Hsp90 association remain
elusive. Because GA binding to Hsp90 uniformly results in client
protein destabilization, GA has proven to be an invaluable tool in
expanding the list of Hsp90-dependent signaling proteins. As the
number of client proteins grows, it seems that a characteristic
shared by many is a functional necessity to form multiprotein
complexes. Whether this proves to be a unifying motif in identify-
ing Hsp90 client proteins remains to be determined.
How does Hsp90 function?
Why does GA almost uniformly cause the destabilization of
Hsp90 client proteins? This requires an understanding of Hsp90
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function. GA and other Hsp90 inhibitors (e.g., radicicol; Sharma et
al., 1998) have not only been used extensively to identify Hsp90
client proteins, but also as probes of Hsp90 function. To this end,
several laboratories simultaneously determined that GA bound to
Hsp90 in a structurally unique amino terminal pocket (Grenert et
al., 1997; Prodromou et al., 1997; Stebbins et al., 1997).
Biochemical and structural studies (Grenert et al., 1997;
Prodromou et al., 1997) identified this pocket as a novel
nucleotide binding domain, thus resolving a long-standing contro-
versy as to whether Hsp90 in fact bound ATP and possessed ATP
hydrolyzing activity. As early as 1993, Csermely had suggested
that ATP bound to Hsp90 and altered its conformation (Csermely
et al., 1993). Although this idea was initially met with some skepti-
cism, the studies described above, as well as others from the lab-
oratories of David Toft and Lawrence Pearl, finally confirmed the
importance of ATP/ADP binding and ATP hydrolysis to the func-
tion of Hsp90 (Grenert et al., 1999; Panaretou et al., 1998).
A model of Hsp90 function has thus emerged in which
nucleotide binding to the amino terminal pocket alters Hsp90
conformation sufficiently to define distinct, nonoverlapping sub-
sets of cochaperone proteins with which Hsp90 interacts, thus
forming a “super-chaperone machine” that cycles between at
least two conformations (Scheibel and Buchner, 1998). An
Hsp90 client protein first associates with an Hsp70/Hsp40
chaperone complex (Hernandez et al., 2002). This assemblage
is next linked to Hsp90 via p60Hop, an Hsp90/Hsp70 interacting
protein. At this point, when the client protein is being loaded on
Hsp90, the chaperone is in its ADP-bound conformation.
Replacement of ADP by ATP in Hsp90 alters its conformation,
releasing p60Hop and the Hsp70/Hsp40 complex, and recruiting
another set of cochaperones, including p23 and certain
immunophilins or p50Cdc37. This association of cochaperones
with Hsp90 folds and stabilizes client proteins, and temporarily
holds them in a state that can bind ligand (e.g., steroid hor-
mones) or respond to a stimulus (e.g., cytosolic kinases).
However, this machine is neither static nor unidirectional. If a
client protein fails to receive its stimulus or see its ligand while it
is in the receptive conformation, the
chaperone cycle will reverse. Upon ATP
hydrolysis, Hsp90 conformation alters,
releasing those cochaperones that asso-
ciate with its ATP-bound state and recruiting those cochaper-
ones that prefer to associate with Hsp90’s ADP-bound
conformation. Although the ATPase activity of Hsp90 is very
weak, it is regulated by both cochaperone association and client
protein binding (McLaughlin et al., 2002; Siligardi et al., 2002;
Young and Hartl, 2000). Most recently, Panaretou and col-
leagues have identified a novel Hsp90 cochaperone, which they
have termed Aha1. Aha1 binding stimulates the inherent
ATPase activity of Hsp90 (Panaretou et al., 2002).
Thus, ATP hydrolysis and ADP/ATP nucleotide exchange
drive the cycling of the Hsp90-based super-chaperone
machine. While a client protein is associated with the ADP-
bound Hsp90-based chaperone complex, it is no longer folded
properly to respond to a stimulus or bind ligand.The mechanism
by which a client protein is targeted for degradation is not well
understood, but may partly depend on the frequency with which
it finds itself in the Hsp70 portion of the cycle, for it is at this
point that the chaperone machine appears capable of recruiting
specific ubiquitinating and proteasome-interacting proteins
which serve to redirect the client protein to the proteasome,
where it is degraded (see Figure 1).
GA (and radicicol) replaces nucleotide in the Hsp90 binding
pocket with an affinity much greater than either ATP or ADP,
thus effectively short-circuiting the chaperone cycle much as a
stick thrust between the spokes of a bicycle wheel precludes
further movement. However, since the GA-bound conformation
of Hsp90 resembles the chaperone’s ADP-bound conformation,
GA binding promotes stable assembly of the super-chaperone
machine that favors client protein degradation (Schneider et al.,
1996). Thus, in the presence of GA, the half-lives of Hsp90
client proteins are uniformly shortened, so that in some cases
their steady-state level becomes undetectable (see Figure 2).
Very recently, several groups have identified E3 ubiquitin ligas-
es containing chaperone-interacting motifs. At least one of
these proteins, CHIP, has been shown to promote the ubiquiti-
nation and degradation of some Hsp90 clients (Connell et al.,
2001), including HER-2 (Xu et al., 2002).
F O C U S
Figure 1. Nucleotide-dependent cycling of the
Hsp90-based super-chaperone machine
Hsp90 forms the basis of a super-chaperone
machine that promotes the proper folding of
client proteins so that they can respond to a
stimulus or bind ligand. However, the machine is
in constant flux and cycles between two Hsp90
conformations, determined by nucleotide bind-
ing, which in turn specify which set of cochaper-
ones associate with the chaperone complex.
Cochaperones that can associate with one
conformation or the other include p23, p50Cdc37,
p60Hop, immunophilins, cyclophilins, Hsp70, Hip,
phosphatase PP5, Hsp40, and BAG-1. Cycling of
this machine is driven by ATP hydrolysis.
Although Hsp90 is a weak ATPase, its activity is
regulated by cochaperones and dramatically
enhanced by client protein binding. A client
protein’s half-life may be stochastically deter-
mined by the length of time it resides in associa-
tion with the Hsp90-Hsp70 form of the
chaperone machine, because at this time, the
client protein is susceptible to ubiquitination
and delivery to the proteasome.
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Translation of Hsp90 inhibition to clinical use in cancer
Because of the wide array of Hsp90 client proteins, the transla-
tional development of Hsp90 inhibitors is taking many directions.
As mentioned above, single agent phase I trials have been run at
multiple institutions examining several different schedules of
drug administration. Using information gained from these multi-
ple phase I studies, targeted phase I/II combination trials and
phase II single agent trials are being developed. The remainder
of this review focuses on 3 Hsp90 clients, p210Bcr-Abl, HER-2, and
HIF-1α/HIF-2α, and describes how inhibition of these proteins
by targeting Hsp90 with 17-AAG (the derivative of GA used clini-
cally) has been incorporated into 3 distinct clinical studies.
Additional phase I/II and phase II studies of 17-AAG alone or in
combination with other chemotherapeutics are being planned,
and some of these are listed in Table 1.
1. Chronic myelogenous leukemia (Hsp90 client: p210Bcr-Abl)
Distinct fusion products of the Bcr and Abl genes, p210Bcr-Abl or
p185Bcr-Abl, have been directly implicated in the development of
chronic myelogenous leukemia (CML) and acute lymphocytic
leukemia (ALL), respectively. We recently reported that the
p210Bcr-Abl protein is dependent on association with Hsp90 for its
stability and that treatment of cells with GA or 17-AAG leads to
rapid destruction of p210Bcr-Abl (Blagosklonny et al., 2001).
Bhalla and colleagues have since reported that high (5 µM)
concentrations of either GA or 17-AAG induced apoptosis in
CML-derived cell lines, as well as in cells transfected with the
Bcr-Abl gene (Nimmanapalli et al., 2001). Shiotsu et al. had pre-
viously shown that the Hsp90 inhibitor radicicol had a similar
proapoptotic effect on p210Bcr-Abl-expressing CML cells in vitro,
and also significantly prolonged the survival of SCID mice inoc-
ulated with K562 cells (Shiotsu et al., 2000). Similar results
have been obtained with imatinib (Gleevec), a moderately spe-
cific Bcr-Abl kinase inhibitor, confirming that inhibition (or degra-
dation) of p210Bcr-Abl is sufficient to induce apoptosis in CML.
However, it is important to note that CML cells that have
become resistant to imatinib in vivo retain their Hsp90 depen-
dence and thus remain sensitive to 17-AAG (Gorre et al., 2002).
Based on these data, a study will soon be commencing at
Karmanos Cancer Institute (Wayne State University) testing the
combination of 17-AAG and imatinib both in patients with accel-
erated or blastic phase CML (where response to imatinib alone
is short-lived), and in chronic phase patients who have failed to
achieve a cytogenetic response with imatinib alone.
2. HER-2-positive breast and prostate cancer (Hsp90
client: HER-2)
HER-2 is one of the most sensitive of the Hsp90 client proteins
to GA and 17-AAG, and both maturing and fully mature forms of
the receptor depend on Hsp90 association for stability (Xu et
al., 2001). HER-2 overexpression is a common phenomenon in
multiple malignancies, and has been associated with develop-
ment of resistance to both chemotherapeutic and biologic
agents (Baselga et al., 1998). Conversely, downregulation of
ErbB2 receptor on cells by using ErbB2-specific monoclonal
antibodies sensitizes ErbB2-overexpressing cancer cells to
chemothrerapeutic agents, such as taxol and doxorubicin
(Baselga et al., 1998). Furthermore, results of a recent clinical
trial demonstrated that the taxol response rate of patients with
HER-2-overexpressing breast cancers was significantly higher
among those receiving taxol plus herceptin compared to those
receiving taxol alone (Pegram et al., 1998). Based on very
promising preclinical data in breast and prostate cancer models
in which 17-AAG markedly enhanced the toxicity of taxol in the
context of HER-2 overexpression (Basso et al., 2002; Solit et al.,
2002), a phase I/II clinical trial is being planned at Memorial
Sloan Kettering Cancer Center to test the efficacy of 17-
AAG/taxol combination in HER-2 overexpressing breast and
prostate cancer.
3.VHL-negative clear cell renal carcinoma (Hsp90 client:
HIF-1α/HIF-2α)
HIF-1 and the highly homologous HIF-2 proteins function as
nuclear transcription factors involved in the transactivation of
numerous target genes, many of which are implicated in the pro-
motion of angiogenesis and adaptation to hypoxia (for a review,
see Harris, 2002). Although these proteins are normally labile
and expressed at low levels in normoxic cells, their stability and
activation increase several-fold in hypoxia. The molecular basis
for the instability of these proteins in normoxia depends upon
VHL, the substrate recognition component of an E3 ubiquitin lig-
F O C U S
Figure 2. GA short-circuits the cycling of the Hsp90-based super-chaperone
machine
When GA or 17-AAG bind in Hsp90’s nucleotide pocket, the drugs’ high
affinity for Hsp90 blocks the cycling of the chaperone machine and alters
Hsp90’s conformation to promote stable assembly of those components
that favor client protein ubiquitination and proteasome delivery.
Table 1. Possible/proposed uses of Hsp90 inhibitors in cancer therapy
Hsp90 inhibitors as single agents in situations in which Hsp90 client protein is
necessary for cancer development or progression
• Bcr-Abl-positive leukemias
• Other leukemias/lymphomas dependent on a chimeric or mutated 
protein (e.g., Flt-3-dependent leukemias, anaplastic large cell 
lymphoma dependent on NPM/ALK)
• Androgen or estrogen receptor-dependent cancers (prostate and
breast)
• Hormone-independent breast and prostate cancers in which receptor
mutation can be documented
• Clear cell renal carcinoma in which pVHL is either inactive or deleted
Hsp90 inhibitors used to enhance response to chemotherapy
• taxol or doxorubicin in HER-2 or AKT over-expressing tumors (breast, 
ovarian, prostate and lung cancer) 
• Gleevec in Bcr-Abl positive leukemias
• proteasome inhibitor in multiple myeloma
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ase complex that targets HIF-1 and HIF-2 for proteasome-
dependent degradation (Maxwell et al., 1999). Hypoxia normally
impairs VHL function, thus allowing HIF to accumulate.
VHL can also be directly inactivated by mutation or hyper-
methylation, resulting in constitutive overexpression of HIF in
normoxic cells. There are two clinical manifestations of VHL
inactivation. In the first, hereditary von Hippel-Lindau disease
arises from genetic loss of VHL, and affected individuals are
predisposed to an increased risk of developing highly vascular
tumors in a number of organs. This is due, in large part, to
deregulated HIF expression and corresponding VEGF upregu-
lation. A common manifestation of VHL disease is the develop-
ment of clear cell renal cell carcinoma (CC-RCC) (Seizinger et
al., 1988).
The second manifestation of VHL inactivation occurs in non-
hereditary, sporadic CC-RCC. Interestingly, although mutations
of VHL are found in most CC-RCCs (Gnarra et al., 1994), they
are absent in other renal tumors, suggesting a dependence
upon HIF activation specifically in RCC development. This is
supported by the finding that all RCC-associated VHL mutants
demonstrate defective ubiquitination of HIF (Ohh et al., 2000).
Furthermore, in the majority of sporadic CC-RCC, HIF-1 over-
expression was detected in tumors, but not in the corresponding
normal kidney (Wiesener et al., 2001), and recent studies sug-
gest that HIF-2 may also be a critical effector of CC-RCC
(Kondo et al., 2002). Overall, the clinical data implicate HIF pro-
teins as critical downstream targets of pVHL that play a major
role in CC-RCC oncogenesis.
HIF interacts with Hsp90 (Gradin et al., 1996) and both GA
and radicicol reduce HIF-dependent transcriptional activity (Hur
et al., 2002; Isaacs et al., 2002; Minet et al., 1999). Hur et al.
demonstrated that HIF from radicicol treated cells was unable to
bind DNA, suggesting that Hsp90 is necessary for mediating
the proper conformation of HIF and/or recruiting additional
cofactors. Additionally, GA downregulates HIF expression by
stimulating the protein’s VHL-independent proteasomal degra-
dation (Isaacs et al., 2002).
Functional inactivation of VHL occurs in approximately 70%
of CC-RCC. While surgery is curative for localized disease,
approximately one-third of patients present with metastatic dis-
ease, for which current treatments are largely ineffective. In
order to examine the effectiveness of Hsp90 inhibition as a
treatment modality in this disease, the National Cancer Institute
is planning a phase II study of 17-AAG in RCC.
Future challenges
From this brief overview, it should be apparent that Hsp90
inhibitors are unique in that, although they are directed toward a
specific molecular target, they simultaneously inhibit multiple
signaling pathways on which cancer cells depend for growth
and survival, thereby perhaps circumventing the characteristic
genetic plasticity that has allowed cancer cells to eventually
evade the toxic effects of most molecularly targeted agents.
However, the complex activity of such drugs will present many
challenges, including how to clinically define the best use of
Hsp90 inhibitors not only as single agents, but also when com-
bined with other chemotherapeutics or signaling modulators
(e.g., tyrosine kinase inhibitors, proteasome inhibitors, taxol,
gemcitibine, and doxorubicin, to name several combinations
that have shown preclinical efficacy). A more complete under-
standing of the biologic activity of Hsp90 and its many cochap-
erones should make this task somewhat easier.
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